ArticleNature protocols2019
V2a interneuron differentiation from mouse and human pluripotent stem cells.
Article in Nature protocols, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Hyaluronic acid-alginate hydrazone crosslinked hydrogels support the generation and maturation of V2a interneurons.Journal of materials chemistry. B · 2026Article
- Distinct differentiation trajectories leave lasting impacts on gene regulation and function of V2a neurons.Nature communications · 2026Article
- Analysis of astrocyte progenitors derived from human induced pluripotent stem cellsbioRxiv : the preprint server for biology · 2025Article
- Combining neural progenitor cell transplant and rehabilitation for enhanced recovery after cervical spinal cord injury.Neural regeneration research · 2024Article
- Neuroplasticity and regeneration after spinal cord injury.North American Spine Society journal · 2023Article
- Organoid models of breathing disorders reveal patterning defect of hindbrain neurons caused by PHOX2B-PARMs.Stem cell reports · 2023Article
- Enrichment of human embryonic stem cell-derived V3 interneurons using an Nkx2-2 gene-specific reporter.Scientific reports · 2023Article
- Modular derivation of diverse, regionally discrete human posterior CNS neurons enables discovery of transcriptomic patterns.Science advances · 2022Article
- Cell-Cell Contact Mediates Gene Expression and Fate Choice of Human Neural Stem/Progenitor Cells.Cells · 2022Article
- Transneuronal tracing to map connectivity in injured and transplanted spinal networks.Experimental neurology · 2022Review
- Cell transplantation to repair the injured spinal cord.International review of neurobiology · 2022Article
- Harnessing Spinal Interneurons for Spinal Cord Repair.Neuroscience insights · 2022Article
- Bioengineering the human spinal cord.Frontiers in cell and developmental biology · 2022Review
- Review
- Induced pluripotent stem cell technology for spinal cord injury: a promising alternative therapy.Neural regeneration research · 2021Article
- Spinal Interneurons as Gatekeepers to Neuroplasticity after Injury or Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Review
- Stem Cell Neurodevelopmental Solutions for Restorative Treatments of the Human Trunk and Spine.Frontiers in cellular neuroscience · 2021Article
- Passive Clearing and 3D Lightsheet Imaging of the Intact and Injured Spinal Cord in Mice.Frontiers in cellular neuroscience · 2021Article
- Article
- Role of Propriospinal Neurons in Control of Respiratory Muscles and Recovery of Breathing Following Injury.Frontiers in systems neuroscience · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
V2a interneurons are located in the hindbrain and spinal cord, where they provide rhythmic input to major motor control centers. Many of the phenotypic properties and functions of excitatory V2a interneurons have yet to be fully defined. Definition of these properties could lead to novel regenerative therapies for traumatic injuries and drug targets for chronic degenerative diseases. Here we describe how to produce V2a interneurons from mouse and human pluripotent stem cells (PSCs), as well as strategies to characterize and mature the cells for further analysis. The described protocols are based on a sequence of small-molecule treatments that induce differentiation of PSCs into V2a interneurons. We also include a detailed description of how to phenotypically characterize, mature, and freeze the cells. The mouse and human protocols are similar in regard to the sequence of small molecules used but differ slightly in the concentrations and durations necessary for induction. With the protocols described, scientists can expect to obtain V2a interneurons with purities of ~75% (mouse) in 7 d and ~50% (human) in 20 d.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.